Skip to main content

Table 1 Characteristics at time of diagnosis in patients with high-grade osteosarcoma

From: A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma

Characteristic

Training cohort (n = 137)

P

Independent validation cohort (n = 54)

P

pGR (n = 57)

Non-pGR (n = 80)

pGR (n = 25)

Non-pGR (n = 29)

Age, years

 Median (range)

16 (4.6–43)

14 (4–46)

0.3939

15 (8–39)

18 (7–44)

0.6123

  ≤ 15 y

27

45

 

13

12

 

  > 15 y

30

35

 

12

17

 

Gender

  

1

  

0.5852

 Male

34

47

 

14

13

 

 Female

23

33

 

11

16

 

Location of primary tumor

  

0.3447

  

0.8041

 Humerus

11

8

 

3

3

 

 Femur

27

45

 

14

17

 

 Tibia and fibula

17

20

 

8

8

 

 Radius and ulna

1

2

 

0

0

 

 Others

1

5

 

0

1

 

Stage at diagnosis

  

1

  

0.3062

 Localized

47

66

 

20

27

 

 Metastatic

10

14

 

5

2

 

Pathologic subtype

  

0.3055

  

0.332

 Osteoblastic

46

55

 

20

19

 

 Chondroblastic

3

13

 

1

5

 

 Fibroblastic

4

4

 

4

4

 

 Telangiectatic

3

5

 

0

1

 

 Others

1

3

 

0

0

 

Type of surgery

  

0.02487*

  

1

 Limb salvage

55

66

 

24

27

 

 Amputation

2

14

 

1

2

 

New pulmonary metastasis

  

1

  

0.9402

 Yes

2

4

 

1

0

 

 No

55

76

 

24

29

 

Chemotherapy regimens

  

0.7224

  

0.4406

 1MTX, DDP and ADM

42

58

 

17

22

 

 2MTX, IFO,DDP and ADM

12

15

 

8

6

 

 3MTX,IFO, DDP and ADM

3

7

 

0

1

 

 Radiomics score

4.4E-4(−1.1–0.72)

−0.55(−2.9–0.32)

2.1E-14

0.030(−0.58–0.71)

−0.31(−2.1–0.34)

2.4E-5

  1. Note: Individual clinical factors were analyzed for significant differences using a nonparametric test. *P < 0.05 indicates a significant difference. Ages and radiomics scores are represented as [Median (range)]. Methotrexate (MTX), Ifosfamide (IFO), Cisplatin (DDP) and Doxorubicin (ADM)